Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
Nadine SchurKapil GudalaUmakanth VudumulaSreelatha VadapalleArjun BhadhuriAlain CasanovaNicholas AdlardMatthias SchwenkglenksPublished in: PharmacoEconomics (2021)
NCT01665144. This economic evaluation was based on the EXPAND trial.